Affimed - AFMD Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AFMD shares.
View AFMD analyst ratings or view top-rated stocks.

5 analysts have issued 1 year price targets for Affimed's shares. Their AFMD share price forecasts range from $2.00 to $12.00. On average, they anticipate the company's stock price to reach $7.50 in the next year. This suggests a possible upside of 258.9% from the stock's current price.
View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts.

Affimed's stock was trading at $5.52 on January 1st, 2022. Since then, AFMD shares have decreased by 62.1% and is now trading at $2.09.
View the best growth stocks for 2022 here.

Affimed saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 3,900,000 shares, a decrease of 8.2% from the October 31st total of 4,250,000 shares. Based on an average trading volume of 1,620,000 shares, the short-interest ratio is presently 2.4 days.
View Affimed's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our AFMD earnings forecast.

Affimed (NASDAQ:AFMD) announced its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company earned $10.21 million during the quarter, compared to the consensus estimate of $11.79 million. Affimed had a negative trailing twelve-month return on equity of 48.46% and a negative net margin of 189.04%. During the same quarter in the previous year, the business posted ($0.08) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN).

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

Affimed's stock is owned by many different institutional and retail investors. Top institutional investors include 683 Capital Management LLC (6.77%), BlackRock Inc. (6.27%), Point72 Asset Management L.P. (4.36%), State Street Corp (1.91%), Stonepine Capital Management LLC (1.60%) and Vanguard Group Inc. (1.13%).

Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AFMD stock can currently be purchased for approximately $2.09.

Affimed (NASDAQ:AFMD) has a market capitalization of $257.95 million and generates $47.76 million in revenue each year. The biopharmaceutical company earns $-68,060,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis.

The company employs 197 workers across the globe.

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for the company is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777.